CLAIMS

1. A compound of Formula (I):



wherein:

One of R^1 and R^2 is H and the other represents – $NHCONHR^4$

wherein R^4 represents a phenyl or naphthyl group (which may be optionally substituted by one or more substituents independently selected from -C_{1-6} alkyl, -C_{1-6} haloalkyl, - $CH_2CH_2CH_2$-, halogen, C_{1-6} alkoxy, C_{1-6} haloalkoxy, OH, NO_2), C_{3-7} cycloalkyl or R^4 together with the NH to which it is bonded forms a morpholino group and

R^3 is H or NHR^5 wherein R^5 is H, -quinolinyl or –isoquinolinyl, -$(CONH)_p$ phenyl (wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -morpholino, -SO_2NH_2, benzothiazole (substituted by methyl))

or a salt, solvate, or physiologically functional derivative thereof.

2. A compound according to claim 1 wherein R^4 represents a phenyl group (which may be optionally substituted by one or more substituents selected from –C_{1-6} haloalkyl, -$CH_2CH_2CH_2$-, halogen) or C_{3-7} cycloalkyl.

3. A compound according to claims 1 – 2 wherein R^3 is H or –NH R^5 where in R^5 is H, quinolinyl, -(CONH)p phenyl (wherein p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, -C_{1-6} haloalkyl –morpholino, -SO_2NH_2, benzothiazole, (substituted by methyl)).

4. A compound according to claims 1 – 3 of formula (1a)



(1a)

wherein one of R^6 and R^7 is H and the other represents -NHCONHR^9;

R^9 represents a phenyl group (which may be optionally substituted by one or more substituents independently selected from -C_{1-6} haloalkyl, -$CH_2CH_2CH_2$-, halogen) or C_{3-7} cycloalkyl;

R^8 is H or NHR^{10};

R^{10} is H quinolinyl, -(CONH)p phenyl (where p is 0 or 1 and the phenyl is optionally substituted by one or more substituents independently selected from halogen, -C_{1-6} haloalkyl, -morpholino, -SO_2NH_2, benzothiazole (substituted by methyl)).

5. A compound according to claim 4 wherein NHCONHR^9 represents



6. A compound according to claim 4 and 5 where in R^{10} is H,



7. A compound as claimed in claim 1 - 6, selected from the group consisting of:
1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-(3-isoquinolin-5-ylphenyl)urea;
1-Cyclohexyl-3-(3-isoquinolin-5-ylphenyl)urea;
1-[3-(1-Amino-isoquinolin-5-yl)-phenyl]-3-(2-fluoro-5-trifluoromethyl-phenyl)-urea ;
1-(2-fluoro-5-trifluoromethyl-phenyl)-3-(5-{3-[3-(2-fluoro-5-trifluoromethyl-phenyl)-ureido]-phenyl}-isoquinolin-1-yl)-urea;
1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-{3-[1-(quinolin-6-ylamino)-isoquinolin-5-yl]-phenyl}-urea;
1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-(4-{1-[4-(6-methyl-benzothiazol-2-yl)-phenylamino]-isoquinolin-5-yl}-phenyl)-urea;
1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-(3-{1-[4-(6-methyl-benzothiazol-2-yl)-phenylamino]-isoquinolin-5-yl}-phenyl)-urea;
1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-(4-isoquinolin-5-ylphenyl)urea;
1-Indan-5-yl-3-(3-isoquinolin-5-yl-phenyl)-urea;
1-(2-Fluoro-5-trifluoromethyl-phenyl)-3-{3-[1-(4-morpholin-4-yl-phenylamino)-isoquinolin-5-yl]-phenyl}-urea;
3-{5-[3-(3-Cyclohexyl-ureido)-phenyl]-isoquinolin-1-ylamino}-benzenesulfonamide;

or a salt, solvate, or physiologically functional derivative thereof.

8. A pharmaceutical composition, comprising: a therapeutically effective amount of a compound as claimed in any one of claims 1 - 7, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

9. A pharmaceutical composition according to claim 8 further comprising an agent to inhibit growth factor receptor function

10. A compound as claimed in any of claims 1 - 7, or a salt, solvate, or a physiologically functional derivative thereof for use in therapy.

11. A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate TIE-2, Eph B4 and VEGFR-2 activity, comprising administering to said mammal a compound according to claims 1 - 7 or a salt, solvate or a physiologically functional derivative thereof.

12. The use of a compound according to claims 1 – 7, or a salt, solvate, or a physiologically functional derivative thereof in the manufacture of a medicament for use in the treatment of a disorder mediated by at least one of inappropriate TIE-2, EphB4 and VEGFR-2 activity.

13. A method of treating a disorder in a mammal, said disorder being mediated by at least one of inappropriate TIE-2, Eph B4 and VEGFR-2 activity, comprising: administering to said mammal (i) a compound according to claims 1 - 7, or a salt, solvate or physiologically functional derivative thereof and (ii) an agent to inhibit growth factor receptor function.

14. The use of a compound according to claims 1 – 7, or a salt, solvate or physiologically functional derivative thereof and an agent to inhibit growth factor receptor function in the manufacture of a medicament for the treatment of a disorder mediated by at least one of inappropriate TIE-2, EphB4 and VEGFR2 activity.

15. A method of treating a disorder in a mammal, said disorder beingcharacterized by inappropriate angiogenesis, comprising administering to said mammal a compound according to claims 1 - 7, or a salt, solvate or physiologically functional derivative thereof.

16. The use of a compound according to claims 1 - 7 or a salt, solvate or physiologically functional derivative thereof in the manufacture of a medicament for the treatment of inappropriate angiogenesis.